IN2013CN00342A - - Google Patents

Info

Publication number
IN2013CN00342A
IN2013CN00342A IN342CHN2013A IN2013CN00342A IN 2013CN00342 A IN2013CN00342 A IN 2013CN00342A IN 342CHN2013 A IN342CHN2013 A IN 342CHN2013A IN 2013CN00342 A IN2013CN00342 A IN 2013CN00342A
Authority
IN
India
Prior art keywords
carrier
agent
renal fibrosis
treating renal
producing
Prior art date
Application number
Inventor
Yoshiro Niitsu
Keiko Kajiwara
Yasunobu Tanaka
Miyono Miyazaki
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of IN2013CN00342A publication Critical patent/IN2013CN00342A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6919—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a ribbon or a tubule cochleate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Abstract

Provided is a carrier for delivering a substance to extracellular matrix producing cells in the kidneys the carrier containing a retinoid as the targeting agent. Also provided is an agent for treating renal fibrosis that uses the carrier. Further provided are methods for producing the carrier and the agent production kits and a method and the like for treating renal fibrosis using the same agent for treating renal fibrosis.
IN342CHN2013 2010-06-17 2011-06-17 IN2013CN00342A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010138070 2010-06-17
PCT/JP2011/063910 WO2011158933A1 (en) 2010-06-17 2011-06-17 Agent for treating renal fibrosis

Publications (1)

Publication Number Publication Date
IN2013CN00342A true IN2013CN00342A (en) 2015-07-03

Family

ID=45348325

Family Applications (1)

Application Number Title Priority Date Filing Date
IN342CHN2013 IN2013CN00342A (en) 2010-06-17 2011-06-17

Country Status (12)

Country Link
US (2) US20130136789A1 (en)
EP (1) EP2583691B1 (en)
JP (2) JP2012020995A (en)
KR (1) KR101967868B1 (en)
CN (1) CN102933233A (en)
AU (1) AU2011266057B2 (en)
CA (1) CA2802414C (en)
ES (1) ES2712086T3 (en)
IN (1) IN2013CN00342A (en)
RU (2) RU2711531C2 (en)
TW (1) TWI549691B (en)
WO (1) WO2011158933A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009221164A (en) 2008-03-17 2009-10-01 Nitto Denko Corp Drug for treating pulmonary fibrosis
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
JP5950428B2 (en) 2010-08-05 2016-07-13 日東電工株式会社 Composition for regenerating normal tissue from fibrotic tissue
JP6340162B2 (en) 2012-12-20 2018-06-06 日東電工株式会社 Apoptosis inducer
CA2935334C (en) 2013-01-18 2021-05-25 Cornell University Methods of treating diseases associated with high fat diet and vitamin a deficiency using retinoic acid receptor agonists
US9976142B2 (en) 2014-04-02 2018-05-22 Nitto Denko Corporation Targeting molecule and a use thereof
JP6480467B2 (en) 2014-04-07 2019-03-13 日東電工株式会社 Novel polymer based hydrotrope for hydrophobic drug delivery
CN105597085A (en) * 2015-12-17 2016-05-25 哈尔滨博翱生物医药技术开发有限公司 Application of fibroblast growth factor-21 in treatment of renal fibrosis
JP6833456B2 (en) * 2016-11-02 2021-02-24 日東電工株式会社 Skin fibrosis treatment agent
KR102352489B1 (en) 2019-12-09 2022-01-18 전남대학교산학협력단 Hydrophobically modified glycol chitosan nanoparticle and renal targeted drug delivery system using the same

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238924A (en) 1984-05-03 1993-08-24 Merck & Co., Inc. Treatment of renal diseases with ace inhibitors
JP3810020B2 (en) 1993-04-22 2006-08-16 武田薬品工業株式会社 Preventive or therapeutic agent for kidney disease
US6183774B1 (en) * 1996-01-31 2001-02-06 Collaborative Laboratories, Inc. Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts
US6334999B1 (en) * 1999-08-27 2002-01-01 Research Development Foundation Liposomal aerosols for delivery of chemotherapeutic retinoids to the lungs
DK1132086T3 (en) 2000-01-31 2006-08-28 Pfizer Prod Inc Use of prostaglandin (PGE2) selective receptor 4 (EP4) agonists for the treatment of acute and chronic renal failure
BR0006556A (en) * 2000-12-28 2002-09-17 Apsen Farmaceutica S A Pharmaceutical composition for topical use of corticosteroids for the treatment of phimosis
IL143366A0 (en) 2001-05-24 2002-04-21 Harasit Medical Res Services & Treatment of renal fibrosis
JP2004043459A (en) 2002-05-24 2004-02-12 Sumitomo Pharmaceut Co Ltd MEDICINE COMPRISING LOW MOLECULAR COMPOUND HAVING TGF-beta INHIBITION ACTIVITY
EP1454625A1 (en) 2003-03-06 2004-09-08 Speedel Development AG Pyridylsulfonamidyl-pyrimidines for the treatment of diabetic nephropathies
EP1746885A4 (en) 2004-05-03 2010-09-08 Univ Virginia Agonists of a2a adenosine receptors for treatment of diabetic nephropathy
KR100613342B1 (en) 2004-12-16 2006-08-21 동부일렉트로닉스 주식회사 Semiconductor device and method of manufacturing the same
JP2009221164A (en) * 2008-03-17 2009-10-01 Nitto Denko Corp Drug for treating pulmonary fibrosis
DK1842557T3 (en) * 2004-12-22 2013-12-02 Nitto Denko Corp Drug carrier and drug carrier kit for inhibiting fibrosis
JP2007099641A (en) 2005-09-30 2007-04-19 Tsumura & Co Indolequinoxaline compound, method for producing the same and pharmaceutical composition using the same
JP5342834B2 (en) * 2008-09-05 2013-11-13 日東電工株式会社 Treatment agent for myelofibrosis
JP2009292725A (en) 2006-09-01 2009-12-17 Stelic Institute Of Regenerative Medicine Kidney disease-improving agent
TWI407971B (en) * 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
JP2009007258A (en) 2007-06-26 2009-01-15 Kowa Pharmaceutical Co Ltd 3-anilino-2-cycloalkenone derivative having inhibitory action on production of pai-1
JP2009029750A (en) 2007-07-27 2009-02-12 Kowa Co Agent comprising arylpropane derivative as effective ingredient for inhibiting formation of advanced glycation end product
WO2009036368A2 (en) * 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
JP2009178143A (en) 2008-02-01 2009-08-13 Stelic Institute Of Regenerative Medicine Steatohepatitis-liver cancer model animal
KR20110051214A (en) * 2008-07-30 2011-05-17 닛토덴코 가부시키가이샤 Drug carriers
JP5744723B2 (en) * 2008-09-12 2015-07-08 日東電工株式会社 Imaging agent for fibrotic diseases
JP2010077101A (en) 2008-09-29 2010-04-08 Toray Ind Inc Curative or preventive agent for kidney fibrosis
TWI465238B (en) * 2009-12-09 2014-12-21 Nitto Denko Corp Modulation of hsp47 expression
DK2718261T3 (en) * 2011-06-08 2016-03-29 Nitto Denko Corp Compounds to target drug delivery and promote siRNA activity

Also Published As

Publication number Publication date
JP2015155459A (en) 2015-08-27
EP2583691A4 (en) 2016-04-27
RU2635460C2 (en) 2017-11-13
US20130136789A1 (en) 2013-05-30
EP2583691B1 (en) 2019-01-16
KR20130121813A (en) 2013-11-06
AU2011266057B2 (en) 2014-12-04
TW201204389A (en) 2012-02-01
TWI549691B (en) 2016-09-21
RU2711531C2 (en) 2020-01-17
CN102933233A (en) 2013-02-13
JP2012020995A (en) 2012-02-02
CA2802414C (en) 2018-01-09
CA2802414A1 (en) 2011-12-22
RU2013101969A (en) 2014-07-27
US20150259683A1 (en) 2015-09-17
ES2712086T3 (en) 2019-05-09
RU2017136720A3 (en) 2019-02-08
AU2011266057A1 (en) 2013-01-10
WO2011158933A1 (en) 2011-12-22
RU2017136720A (en) 2019-02-08
JP5873589B2 (en) 2016-03-01
EP2583691A1 (en) 2013-04-24
KR101967868B1 (en) 2019-08-19

Similar Documents

Publication Publication Date Title
IN2013CN00342A (en)
MX354137B (en) Topical minocycline compositions and methods of using the same.
MX2011005893A (en) Utility scale osmotic grid storage.
EP2663337A4 (en) Method for delivering agents into cells using bacterial toxins
NZ717728A (en) Stable formulations of a hyaluronan-degrading enzyme
GB2510091A (en) Collaborative processor and system performance and power management
MX348537B (en) Differentiation of pluripotent stem cells.
GEP201706733B (en) Anti-il-23 antibodies
EP2751632A4 (en) System and method for forcing data center power consumption to specific levels by dynamically adjusting equipment utilization
PT2710123T (en) Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof
EP2639293A4 (en) Cell culture chamber, method for producing same, tissue model using cell culture chamber, and method for producing same
EP2727283A4 (en) Apparatus, method and system for creating and maintaining multicast data encryption key in machine to machine communication system
EP2696411A4 (en) Lithium iron phosphate positive electrode material, and method for producing same
EP2755291B8 (en) Vehicle charging system, vehicle charging method, power supply system, and power supply method
IN2014MN00908A (en)
AU342950S (en) Utility pump
MY170511A (en) Colonoscopy-preparation
MX2013009780A (en) Methods, apparatuses and systems for calculating an amount to be billed in respect of running an out-of-home advertisement during a period of time.
EP4219395A3 (en) Novel metal hydrides and their use in hydrogen storage applications
MX2016000557A (en) Small molecule based conversion of somatic cells into neural crest cells.
MX344896B (en) Fermentation process involving adjusting specific co-uptake.
MX354183B (en) Method of operation of fermentation of gaseous substrate comprising hydrogen.
PH12014501240A1 (en) Film containing compositions
AR089156A1 (en) METHOD FOR THE EXTRACTION OF LITHIUM FROM A LITIO CARRIER SOLUTION
EP2752933A4 (en) Battery electrolyte and method for producing same, and battery comprising electrolyte